We offer over 1,400 small-molecule analogs of known aspartic proteinase inhibitors, selected with a 2D fingerprint similarity. Moreover, our docking-based virtual screening has provided over 2,300 drug-like screening compounds with potential renin-binding activity. Being part of RAAS, the renin inhibition may give a new insight into anti-coronavirus and hypertension drug discovery.

Life Chemicals has developed two screening compound subsets using 2D fingerprint similarity search (3,500 compounds) and docking-based virtual screening (8,000 compounds) to boost epigenetic-related drug discovery efforts. The selected structurally-diverse molecules are predicted to modulate a number of most promising epigenetic targets.

We offer a recently-updated collection of over 49,000 fragments, readily available for fragment-based lead discovery (FBLD) projects. Specific subsets are available to provide the most suitable solutions for different research approaches (such as NMR, high-throughput X-ray crystallography, high concentration bioassay, SPR). Explore our Fsp3-enriched and 3D fragments, fluorinated, brominated and covalent fragments, high solubility subset, and many more.

ATPases are crucial enzymes engaged in energy homeostasis and signal transduction. Mutations in these proteins account for various diseases from cancer to osteoporosis, immune deficiency disease, nephrotoxicity, cystic fibrosis, and diabetes. We have selected over 8,800 drug-like screening compounds with potential ATPase inhibitory activity for drug discovery HTS projects. A pre-plated set based on this Screening Library is also available.

Ligases are enzymes that catalyze the reaction of joining two large molecules by establishing a new chemical bond. They play an important role in tumorigenesis and cancer development. Life Chemicals has recently designed a new screening set containing drug-like small-molecule analogs of reported ligase inhibitors against over 20 ligase enzyme targets.

Many of the most prevalent and deadly human diseases are caused by a protozoan infection, including malaria, African Sleeping Sickness, and amoebic dysentery. We have prepared a collection of over 8,200 drug-like screening compounds with potential antiprotozoal activity against major protozoan diseases applying a ligand-based approach. The compound set is aimed as a starting point for antiprotozoal drug discovery efforts.

Keeping pace with a growing interest in the inhibition of Protein-protein interactions (PPIs) with small molecules, Life Chemicals offers a proprietary collection of potential PPI modulators. PPI-focused screening compounds were selected by both ligand-based and receptor-based approaches.

Antibacterial Screening Library by Life Chemicals contains drug-like screening compounds with potential antibacterial activity against different gram-positive and gram-negative bacteria species and bacteria-related protein targets. It is a product to enjoy in your HTS and HCS for antibacterial drug discovery projects.